{
    "root": "e6c6ca31-24d4-45e9-8fe9-b9c880a475f8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Incruse Ellipta",
    "value": "20231213",
    "ingredients": [
        {
            "name": "UMECLIDINIUM BROMIDE",
            "code": "7AN603V4JV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_79040"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        }
    ],
    "indications": {
        "text": "incruse ellipta indicated maintenance treatment patients chronic obstructive pulmonary disease ( chronic obstructive pulmonary disease ) .",
        "doid_entities": [
            {
                "text": "chronic obstructive pulmonary disease (DOID:3083)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3083"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended incruse ellipta maintenance treatment chronic obstructive pulmonary disease 1 actuation ( umeclidinium 62.5 mcg ) daily oral inhalation . \u2022incruse ellipta used time every day . incruse ellipta 1 time every 24 hours . \u2022no adjustment required geriatric patients , patients renal impairment , patients moderate hepatic impairment [ pharmacology ( 12.3 ) ] .",
        "doid_entities": [
            {
                "text": "chronic obstructive pulmonary disease (DOID:3083)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3083"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "incruse ellipta supplied disposable light grey light green plastic inhaler containing foil strip 30 blisters ( ndc 0173-0873-10 ) 7 blisters ( institutional pack ) ( ndc 0173-0873-06 ) . inhaler packaged moisture-protective foil tray desiccant peelable lid . store room temperature 68\u00b0f 77\u00b0f ( 20\u00b0c 25\u00b0c ) ; excursions permitted 59\u00b0f 86\u00b0f ( 15\u00b0c 30\u00b0c ) [ usp controlled room temperature ] . store dry place away direct heat sunlight . keep reach children . incruse ellipta stored inside unopened moisture-protective foil tray removed tray immediately initial . discard incruse ellipta 6 weeks opening foil tray counter reads \u201c 0 \u201d ( blisters used ) , whichever comes first . inhaler reusable . attempt take inhaler apart .",
    "adverseReactions": "incruse ellipta contraindicated following conditions : \u2022severe hypersensitivity milk proteins [ ( 5.3 ) ] \u2022hypersensitivity umeclidinium excipients [ ( 5.3 ) , description ( 11 ) ]",
    "indications_original": "INCRUSE ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).",
    "contraindications_original": "The recommended dosage of INCRUSE ELLIPTA for maintenance treatment of COPD is 1 actuation (umeclidinium 62.5 mcg) once daily by oral inhalation.\n                  \n                     \n                        \u2022INCRUSE ELLIPTA should be used at the same time every day. Do not use INCRUSE ELLIPTA more than 1 time every 24 hours.\n                     \n                        \u2022No dosage adjustment is required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment [see Clinical Pharmacology (12.3)].",
    "warningsAndPrecautions_original": "INCRUSE ELLIPTA is supplied as a disposable light grey and light green plastic inhaler containing a foil strip with 30 blisters (NDC 0173-0873-10) or 7 blisters (institutional pack) (NDC 0173-0873-06).\n                  The inhaler is packaged in a moisture-protective foil tray with a desiccant and a peelable lid.\n                  Store at room temperature between 68\u00b0F and 77\u00b0F (20\u00b0C and 25\u00b0C); excursions permitted from 59\u00b0F to 86\u00b0F (15\u00b0C to 30\u00b0C) [See USP Controlled Room Temperature]. Store in a dry place away from direct heat or sunlight. Keep out of reach of children. \n                  INCRUSE ELLIPTA should be stored inside the unopened moisture-protective foil tray and only removed from the tray immediately before initial use. Discard INCRUSE ELLIPTA 6 weeks after opening the foil tray or when the counter reads \u201c0\u201d (after all blisters have been used), whichever comes first. The inhaler is not reusable. Do not attempt to take the inhaler apart.",
    "adverseReactions_original": "INCRUSE ELLIPTA is contraindicated in the following conditions:\n                  \n                     \n                        \u2022Severe hypersensitivity to milk proteins [see Warnings and Precautions (5.3)]\n                     \n                     \n                        \u2022Hypersensitivity to umeclidinium or any of the excipients [see Warnings and Precautions (5.3), Description (11)]",
    "drug": [
        {
            "name": "Incruse Ellipta",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_79040"
        }
    ]
}